A diverse collection of news items, studies, and interesting facts from November 2024, covering topics from scientific discoveries to cultural phenomena. Longer summary

This post is a compilation of various news items, studies, and interesting facts from November 2024. It covers a wide range of topics including scientific discoveries, political events, technological advancements, cultural phenomena, and historical anecdotes. The post is structured as a numbered list, with each item briefly summarizing a piece of news or information. Some notable items include a new schizophrenia drug approval, YouGov polling results on various historical figures, findings on genetic IQ changes over time, and updates on AI technology and its implications. Shorter summary

Scott Alexander evaluates silexan, a lavender-based anxiety supplement, finding promising but potentially biased evidence, and recommends cautious trial use. Longer summary

Scott Alexander reviews the evidence for silexan, a lavender-derived supplement claimed to be highly effective for anxiety. He examines the studies, noting that most are by one researcher with conflicts of interest, but finds the methodology generally sound. He also considers circumstantial evidence, including animal studies and anecdotal reports. While cautioning about the lack of independent research, Scott concludes that silexan is worth trying due to its low risk and potential benefits, and predicts a 50% chance it will prove as effective as SSRIs for anxiety in future independent studies. Shorter summary

Scott Alexander presents a detailed guide on depression, covering its causes, symptoms, and various treatment options, including lifestyle changes, therapies, medications, and other interventions. Longer summary

Scott Alexander provides a comprehensive guide on depression, covering its causes, symptoms, and various treatment options. He discusses lifestyle changes, therapies, medications, supplements, and other interventions like TMS and ECT. The post offers practical advice on how to approach treatment, including specific regimens for different situations, and guidelines on how long to continue treatment once it starts working. Shorter summary

Scott Alexander examines the development and effectiveness of vilazodone and vortioxetine, two antidepressants designed to work faster and better than SSRIs, but which ultimately failed to live up to expectations. Longer summary

Scott Alexander discusses the development and effectiveness of two antidepressants, vilazodone and vortioxetine, which were designed to combine SSRI effects with 5-HT1A partial agonism. He explains the theoretical basis for their development, involving the role of presynaptic 5-HT1A autoreceptors in delaying SSRI effectiveness. The post then evaluates the clinical performance of these drugs, finding that despite their innovative design, they don't significantly outperform older antidepressants in efficacy, onset speed, or side effect profile. Scott expresses confusion about the theoretical underpinnings of these drugs and why pharmaceutical companies invested so heavily in their development. Shorter summary

Scott Alexander critically examines pharmacogenomic testing for antidepressants, particularly the GeneSight test, expressing skepticism about its current effectiveness and validity. Longer summary

Scott Alexander critically examines the field of pharmacogenomics for antidepressants, particularly focusing on the GeneSight test. He reviews the scientific evidence, discusses potential flaws in studies, and expresses skepticism about the current state and effectiveness of such testing. The post delves into the complexities of antidepressant metabolism, the challenges of predicting drug response, and the limitations of current genetic testing approaches. Shorter summary

Scott Alexander defends psychiatry's use of 'chemical imbalance' theory, arguing it was meant to emphasize depression's biological basis rather than claiming a simple serotonin deficiency. Longer summary

Scott Alexander responds to criticisms of psychiatry's use of the 'chemical imbalance' theory of depression. He argues that psychiatrists never claimed depression was simply a serotonin deficiency, but rather a complex interaction of brain chemicals. He explains that the term 'chemical imbalance' was used to emphasize depression's biological basis and help people take it seriously, rather than viewing it as a personal failure. Scott provides evidence that serotonin and other neurotransmitters are indeed involved in depression, while acknowledging the full picture is more complicated. He concludes that framing depression in terms of brain chemistry remains useful, even if 'chemical imbalance' is no longer the best terminology. Shorter summary